Novo Nordisk halts two more Ziltivekimab trials as shares slide ~10% since July

On 7 September 2026 Novo Nordisk said it was ending two further clinical studies of its experimental heart‑failure drug Ziltivekimab, a move that follows an earlier trial that failed to show any reduction in heart‑attack or stroke risk. The announcement coincided with a 0.6 % fall in the company’s Copenhagen‑listed share price and brings the total decline since the end‑July failure report to roughly 10 %.

Additional trial terminations

According to Handelsblatt, Novo Nordisk stopped two more studies that were evaluating whether Ziltivekimab could help patients with heart failure. The spokesperson for the company told the newspaper that “in den beiden nun gestoppten Studien gebe es nur eine geringe Wahrscheinlichkeit für ein anderes Ergebnis als in der vorherigen Untersuchung” (the two newly stopped studies have only a low probability of a different outcome than the previous investigation). The decision reflects the company’s assessment that the drug is unlikely to achieve a positive efficacy signal.

Earlier efficacy setback

Handelsblatt also reported that at the start of 2026 Novo Nordisk disclosed that Ziltivekimab did not reduce the risk of myocardial infarction or stroke in a separate clinical trial. That earlier negative result had already dampened expectations for the pipeline and set the stage for the later terminations.

Share‑price reaction

The immediate market response to the 7 September announcement was a 0.6 % decline in Novo Nordisk’s share price on the Copenhagen exchange (period: after announcement, Monday 2026‑09‑07) – a figure supplied directly by Handelsblatt. Since the end‑July disclosure of the first study’s failure, the stock has fallen about 10 % (period: July 2026 – September 2026), also reported by Handelsblatt. The cumulative move underscores how investors have priced in the growing uncertainty around the drug’s commercial prospects.

Company background

Novo Nordisk A/S is a Danish pharmaceutical group headquartered in Bagsværd, Denmark. The firm employs roughly 42,446 people and is listed on the New York Stock Exchange under the ticker NVO (source: SEC filing). Lars Fruergaard Jørgensen serves as chief executive officer, a fact confirmed in the latest company filings (source: company research). The company’s fiscal year ends on 31 December (fiscal‑year‑end: 1231) and its primary focus is on diabetes care, obesity, and a growing portfolio of cardiovascular and rare‑disease medicines.

Timeline of events

• Early 2026 – Novo Nordisk announced that Ziltivekimab failed to lower heart‑attack or stroke risk in a clinical study.
• End July 2026 – The company publicly reported the failure of that Ziltivekimab study.
• 7 September 2026 – Novo Nordisk halted two additional Ziltivekimab trials; shares fell 0.6 % in Copenhagen.

Each step has been documented by Handelsblatt, which provides the only source for the trial outcomes and share‑price movements in this packet.

Implications for investors and the market

The cessation of the two studies reduces Novo Nordisk’s near‑term R&D outlay on Ziltivekimab, but it also eliminates any chance that the drug could become a revenue generator. For investors, the roughly 10 % slide since July reflects a reassessment of the company’s growth pipeline beyond its core diabetes and obesity products. Analysts will likely re‑weight earnings forecasts to exclude any potential upside from Ziltivekimab, while still factoring in the firm’s robust cash flow from existing products.

What remains unknown

Novo Nordisk has not disclosed how many patients were enrolled in the two halted trials, nor the exact financial impact of terminating them. The company also did not comment on whether it will pursue alternative cardiovascular candidates or shift resources to other late‑stage programs. These gaps mean that the full cost of the setbacks cannot be quantified at this stage.

In summary, Novo Nordisk’s decision to stop two further Ziltivekimab investigations adds to an earlier efficacy failure, and the market has responded with a cumulative ~10 % decline in the share price since July. The outcome underscores the high risk inherent in cardiovascular drug development and highlights the importance of clear efficacy signals for investor confidence.